

Sepsis Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Glycopeptide, Aminoglycosides), By Route Of Administration (Parenteral, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

<https://marketpublishers.com/r/S75438889190EN.html>

Date: January 2025

Pages: 153

Price: US\$ 5,950.00 (Single User License)

ID: S75438889190EN

Abstracts

This report can be delivered to the clients within 3 Business Days

Sepsis Therapeutics Market Growth & Trends

The global sepsis therapeutics market size is anticipated to reach USD 5.64 billion by 2030, growing at a CAGR of 6.18% from 2025 to 2030, according to a new report by Grand View Research, Inc. The sepsis therapeutics industry is experiencing significant growth due to the increasing prevalence of sepsis and the rising demand for effective treatment options. Sepsis, a life-threatening condition triggered by an infection, is a leading cause of mortality globally, particularly among vulnerable populations such as the elderly and those with compromised immune systems. The growing awareness about sepsis, alongside advancements in healthcare infrastructure, is driving the demand for novel and effective therapies, propelling market growth.

A key factor contributing to the expansion of the market is the wide range of antibiotics used in the treatment. Aminoglycosides, such as gentamicin, continue to be a mainstay in sepsis management due to their broad-spectrum activity against Gram-negative bacteria. Additionally, cephalosporins are widely prescribed because of their effectiveness in treating various infections, especially those caused by Gram-positive bacteria. Glycopeptides, such as vancomycin, are also critical in

sepsis therapy, particularly for resistant infections. The presence of other drug classes like carbapenems and beta-lactams further enhances the treatment landscape.

The availability of sepsis therapeutics in various forms, including oral, parenteral (injectable), and other formulations, ensures better accessibility and versatility for patients across different healthcare settings. Oral medications are convenient for outpatient treatment, while parenteral formulations are vital for severe cases requiring immediate intervention. The growing availability of other drug forms also supports personalized care.

In terms of distribution channels, hospital pharmacies continue to be the primary source of sepsis therapeutics, ensuring that critical care units are stocked with necessary treatments. Retail pharmacies are expanding their role in providing accessible medications, while online pharmacies are gaining traction by offering easy access to sepsis drugs, further boosting market growth. As healthcare access and treatment awareness increase globally, the sepsis therapeutics industry is poised for continued expansion in the coming years.

Sepsis Therapeutics Market Report Highlights

The drug class segment of cephalosporins held the largest market share in 2024. This dominance can be attributed to the broad-spectrum efficacy of cephalosporins against a wide range of bacterial infections, including both Gram-positive and Gram-negative pathogens.

In the route of administration segment, parenteral formulations dominated the market in 2024. Parenteral drugs, including intravenous and intramuscular injections, offer rapid delivery and higher bioavailability, making them essential for the immediate treatment of sepsis, especially in critical care settings.

Based on distribution channel, hospital pharmacies remained the dominant segment in 2024. Hospital pharmacies are critical in ensuring timely and adequate provision of sepsis therapeutics, particularly in intensive care units (ICUs) and emergency departments where quick access to lifesaving treatments is essential.

North America dominated the market for sepsis therapeutics in 2024, owing to factors such as advanced healthcare infrastructure, rising disease prevalence, and favorable regulatory environment.

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
 - 1.3.1. Information Procurement
 - 1.3.2. Information or Data Analysis
 - 1.3.3. Market Formulation & Data Visualization
 - 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
 - 1.4.1. List of Data Sources

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights

CHAPTER 3. SEPSIS THERAPEUTICS MARKET VARIABLES, TRENDS, & SCOPE

- 3.1. Parent Market Outlook
- 3.2. Ancillary Market Outlook
- 3.3. Market Dynamics
 - 3.3.1. Market Drivers Analysis
 - 3.3.1.1. Increasing prevalence of sepsis cases
 - 3.3.1.2. Advancements in modern therapeutics
 - 3.3.1.3. Rising investment in sepsis research and drug development
 - 3.3.2. Market Restraints Analysis
 - 3.3.2.1. High cost of advanced therapies
 - 3.3.2.2. Lack of awareness and early diagnosis in some regions
- 3.4. Sepsis Therapeutics Analysis Tools
 - 3.4.1. Porter's Analysis
 - 3.4.1.1. Bargaining power of the suppliers
 - 3.4.1.2. Bargaining power of the buyers
 - 3.4.1.3. Threats of substitution
 - 3.4.1.4. Threats from new entrants
 - 3.4.1.5. Competitive rivalry

3.4.2. PESTEL Analysis

3.4.2.1. Political landscape

3.4.2.2. Economic and Social landscape

3.4.2.3. Technological landscape

3.4.2.4. Environmental landscape

3.4.2.5. Legal landscape

CHAPTER 4. SEPSIS THERAPEUTICS MARKET: TYPE ESTIMATES & TREND ANALYSIS

4.1. Sepsis Therapeutics Market: Type Segment Dashboard

4.2. Sepsis Therapeutics Market: By Type Movement Analysis, 2024 & 2030 (USD Million)

4.3. Cephalosporin

4.3.1. Cephalosporin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

4.4. Aminoglycosides

4.4.1. Aminoglycosides Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

4.5. Glycopeptide

4.5.1. Glycopeptide Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

4.6. Other Drug Class

4.6.1. Other Drug Class Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 5. SEPSIS THERAPEUTICS MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS

5.1. Sepsis Therapeutics Market: Route of Administration Segment Dashboard

5.2. Sepsis Therapeutics Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)

5.3. Parenteral

5.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

5.4. Oral

5.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

5.5. Others

5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 6. SEPSIS THERAPEUTICS MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS

- 6.1. Sepsis Therapeutics Market: Distribution Channel Segment Dashboard
- 6.2. Sepsis Therapeutics Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
- 6.3. Hospital Pharmacies
 - 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Retail Pharmacies
 - 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Online Pharmacies
 - 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 7. SEPSIS THERAPEUTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

- 7.1. Sepsis Therapeutics Market Share, By Region, 2024 & 2030 (USD Million)
- 7.2. North America
 - 7.2.1. North America Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
 - 7.2.2. U.S.
 - 7.2.2.1. U.S. Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
 - 7.2.3. Canada
 - 7.2.3.1. Canada Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
 - 7.2.4. Mexico
 - 7.2.4.1. Mexico Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3. Europe
 - 7.3.1. Europe Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
 - 7.3.2. UK
 - 7.3.2.1. UK Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
 - 7.3.3. Germany

7.3.3.1. Germany Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030
(USD Million)

7.3.4. France

7.3.4.1. France Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030
(USD Million)

7.3.5. Italy

7.3.5.1. Italy Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030
(USD Million)

7.3.6. Spain

7.3.6.1. Spain Sepsis Therapeutics Market Estimates and Forecasts, 2018– 2030
(USD Million)

7.3.7. Denmark

7.3.7.1. Denmark Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030
(USD Million)

7.3.8. Norway

7.3.8.1. Norway Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030
(USD Million)

7.3.9. Sweden

7.3.9.1. Sweden Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030
(USD Million)

7.4. Asia Pacific

7.4.1. Asia Pacific Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030
(USD Million)

7.4.2. China

7.4.2.1. China Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030
(USD Million)

7.4.3. Japan

7.4.3.1. Japan Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030
(USD Million)

7.4.4. India

7.4.4.1. India Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030
(USD Million)

7.4.5. South Korea

7.4.5.1. South Korea Sepsis Therapeutics Market Estimates and Forecasts, 2018 -
2030 (USD Million)

7.4.6. Australia

7.4.6.1. Australia Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030
(USD Million)

7.4.7. Thailand

7.4.7.1. Thailand Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030
(USD Million)

7.5. Latin America

7.5.1. Latin America Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.5.2. Brazil

7.5.2.1. Brazil Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.5.3. Argentina

7.5.3.1. Argentina Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.6. Middle East and Africa

7.6.1. Middle East and Africa Sepsis Therapeutics Market Estimates and Forecasts, 2017 – 2030 (USD Million)

7.6.2. Saudi Arabia

7.6.2.1. Saudi Arabia Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.6.3. UAE

7.6.3.1. UAE Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.6.4. Kuwait

7.6.4.1. Kuwait Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

7.6.5. South Africa

7.6.5.1. South Africa Sepsis Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

CHAPTER 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments & Impact Analysis by Key Market Participants

8.2. Company Categorization

8.3. Company Heat Map Analysis

8.4. Company Profiles

8.4.1. Pfizer, Inc.

8.4.1.1. Participant's Overview

8.4.1.2. Financial Performance

8.4.1.3. Product Benchmarking

8.4.1.4. Recent Developments/ Strategic Initiatives

8.4.2. GSK plc.

- 8.4.2.1. Participant's Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. AstraZeneca
 - 8.4.3.1. Participant's Overview
 - 8.4.3.2. Financial Performance
 - 8.4.3.3. Product Benchmarking
 - 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Eli Lilly and Company
 - 8.4.4.1. Participant's Overview
 - 8.4.4.2. Financial Performance
 - 8.4.4.3. Product Benchmarking
 - 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Astellas Pharma Inc.
 - 8.4.5.1. Participant's Overview
 - 8.4.5.2. Financial Performance
 - 8.4.5.3. Product Benchmarking
 - 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Asahi Kasei Corporation
 - 8.4.6.1. Participant's Overview
 - 8.4.6.2. Financial Performance
 - 8.4.6.3. Product Benchmarking
 - 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. InflaRx GmbH
 - 8.4.7.1. Participant's Overview
 - 8.4.7.2. Financial Performance
 - 8.4.7.3. Product Benchmarking
 - 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. La Jolla Pharmaceutical Co.
 - 8.4.8.1. Participant's Overview
 - 8.4.8.2. Financial Performance
 - 8.4.8.3. Product Benchmarking
 - 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. T2 Biosystems Inc.
 - 8.4.9.1. Participant's Overview
 - 8.4.9.2. Financial Performance
 - 8.4.9.3. Product Benchmarking
 - 8.4.9.4. Recent Developments/ Strategic Initiatives

8.4.10. Aridis Pharmaceuticals Inc.

8.4.10.1. Participant's Overview

8.4.10.2. Financial Performance

8.4.10.3. Product Benchmarking

8.4.10.4. Recent Developments/ Strategic Initiatives

I would like to order

Product name: Sepsis Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Glycopeptide, Aminoglycosides), By Route Of Administration (Parenteral, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

Product link: <https://marketpublishers.com/r/S75438889190EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S75438889190EN.html>